Is Zimmer Holdings the Perfect Stock?

Everyone would love to find the perfect stock. But will you ever really find a stock that gives you everything you could possibly want?

One thing's for sure: If you don't look, you'll never find truly great investments. So let's first take a look at what you'd want to see from a perfect stock, and then decide if Zimmer Holdings (NYSE: ZMH  ) fits the bill.

The quest for perfection
When you're looking for great stocks, you have to do your due diligence. It's not enough to rely on a single measure, because a stock that looks great based on one factor may turn out to be horrible in other ways. The best stocks, however, excel in many different areas, which all come together to make up a very attractive picture.

Some of the most basic yet important things to look for in a stock are:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
  • Margins. Higher sales don't mean anything if a company can't turn them into profits. Strong margins ensure a company is able to turn revenue into profit.
  • Balance sheet. Debt-laden companies have banks and bondholders competing with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
  • Money-making opportunities. Companies need to be able to turn their resources into profitable business opportunities. Return on equity helps measure how well a company is finding those opportunities.
  • Valuation. You can't afford to pay too much for even the best companies. Earnings multiples are simple, but using normalized figures gives you a sense of how valuation fits into a longer-term context.
  • Dividends. Investors are demanding tangible proof of profits, and there's nothing more tangible than getting a check every three months. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at Zimmer.

Factor What We Want to See Actual Pass or Fail?
Growth 5-year annual revenue growth > 15% 5.1% Fail
  1-year revenue growth > 12% 3% Fail
Margins Gross margin > 35% 76% Pass
  Net margin > 15% 14.1% Fail
Balance sheet Debt to equity < 50% 19.8% Pass
  Current ratio > 1.3 4.28 Pass
Opportunities Return on equity > 15% 10.5% Fail
Valuation Normalized P/E < 20 17.80 Pass
Dividends Current yield > 2% 0% Fail
  5-year dividend growth > 10% 0% Fail
       
  Total Score   4 out of 10

Source: Capital IQ, a division of Standard & Poor's. Total score = number of passes.

With a score of four, Zimmer isn't perfect. But the company is in a great place to capitalize on demographic trends, making the future look even brighter for shareholders.

Zimmer is a top maker of knee and hip replacements. Only a few competitors, including Stryker (NYSE: SYK  ) , Smith & Nephew (NYSE: SNN  ) , and Johnson & Johnson's (NYSE: JNJ  ) DePuy division, go up against Zimmer in the area. But the industry has huge growth potential because of the aging U.S. population needing more of its products.

The problem with Zimmer is that it hasn't executed on the promise of its industry very well. It has the lowest return on equity of its peer group, and because both Stryker and Smith & Nephew have found ways to grow revenue faster than Zimmer, Zimmer has lost market share. And from a shareholder's perspective, Zimmer is the only company that doesn't pay a dividend. Yet despite its shortfalls, Zimmer doesn't trade at much of a valuation discount to its competitors.

Zimmer is in the right place at the right time. The question is whether it will capitalize on its potential. Unless the company can reverse its recent mistakes, Zimmer could very well find itself the odd one out in the joint replacement health care niche.

Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.

Click here to add Zimmer Holdings to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Fool contributor Dan Caplinger doesn't own shares of the companies mentioned in this article. Johnson & Johnson and Stryker are Motley Fool Inside Value picks. Smith & Nephew is a Motley Fool Global Gains recommendation. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson, which is also a Motley Fool Income Investor recommendation. The Fool owns shares of Johnson & Johnson and Zimmer Holdings. Motley Fool Alpha owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1441709, ~/Articles/ArticleHandler.aspx, 11/23/2014 6:33:53 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement